Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The efficacy and optimal dose of the new acid-suppressant vonoprazan (VPZ) for quadruple therapy remain uncertain. This study aimed to compare the efficacy and safety of 20 mg VPZ daily (VOD) and 20 mg VPZ twice daily (VTD) with a proton pump inhibitor (PPI) twice daily in quadruple therapy.
Methods: We retrospectively analyzed the data of 954 patients treated with quadruple therapy to eradicate . Eradication rates and adverse events were compared between the VOD and VTD groups, and between the VOD and PPI groups. Multivariate analysis was conducted to identify the predictors of eradication failure.
Results: Eradication was successful in 875 (91.7%) of the 954 patients. The total, initial, and rescue eradication rates in the VOD group were 92.1%, 93.3%, and 77.8%, respectively. In both the crude and multivariate analyses, the VOD group showed eradication rates comparable to those of the VTD and PPI groups (all >0.05). Age > 60 years (odds ratio [OR] = 2.165, =0.012) and use of rescue therapy (OR = 3.496, <0.001) were independent risk factors for eradication failure, whereas VPZ at a low dosing frequency of 20 mg daily was not. A total of 787 patients (82.5%) were followed up (mean follow-up time, 6.7 ± 2.0 months). Compared with the VOD group, the VTD group was more likely to experience adverse events (OR = 2.073, =0.035).
Conclusion: VPZ at a low dose of 20 mg daily is an effective and safe component of the quadruple therapy for eradication.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11018536 | PMC |
| http://dx.doi.org/10.1093/gastro/goae036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Screening and eradication of or gastric cancer prevention: Taipei Global Consensus II.
Gut
September 2025
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Objective: To convene a global consensus on () screening and eradication strategies for gastric cancer prevention, identify key knowledge gaps and outline future research directions.
Methods: 32 experts from 12 countries developed and refined consensus statements on management, using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to assess evidence and the Delphi method to achieve ≥80% agreement.
Results: Consensus was achieved on 28 statements.
Superior Efficacy of Bismuth-Containing Rifabutin Quadruple Therapy over Rifabutin Triple Therapy as Salvage Treatment.
Gut Liver
September 2025
Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Background/aims: Helicobacter pylori is a pathogen that causes chronic gastritis and peptic ulcer diseases and is a carcinogen responsible for the development of malignancies, including gastric cancer. In the current era of high antimicrobial resistance, rifabutin-based triple therapy is recommended as a salvage therapy. Bismuth has not only a strong bacteriostatic effect but also a synergic effect when combined with antibiotics.
View Article and Find Full Text PDFAntimicrobial drug susceptibility testing for the management of infection in personalized eradication therapy.
Front Microbiol
August 2025
Department of Gastroenterology, Lanzhou University Second Hospital, Lanzhou, China.
is a gram-negative bacterium that associated with diseases such as gastritis, peptic ulcer and gastric cancer. In recent years, various treatment options have been evaluated, such as bismuth-containing quadruple therapy, high-dose dual therapy, and the use of acid-suppressing drugs such as Vonoprazan, however, the effectiveness of eradication treatment is still dramatically decreasing due to the rising antibiotic resistance rate, and successful eradication of has become a major public health problem. Therefore a promising strategy against drug-resistant is to individualize treatment based on the outcome of antibiotic resistance.
View Article and Find Full Text PDFGlobal real-world data on Heart Failure with reduced Ejection Fraction (HFrEF): challenges in optimisation and sex disparities.
Eur Heart J Qual Care Clin Outcomes
September 2025
Cardiology University Department, IRCCS Policlinico San Donato, Piazza Edmondo Malan, Milan 20097, Italy.
Background And Aims: Despite the advancements in the treatment of patients with heart failure with reduced ejection fraction (HFrEF), clinical inertia regarding the prescription of the four classes of guidelines-directed medical therapies (GDMT) remains prevalent. This study aims to assess how adherence and time of prescription to GDMT in HFrEF impact mortality. Additionally, it seeks to evaluate sex differences in prescription, and outcome.
View Article and Find Full Text PDFPharmacological Treatment of Heart Failure with Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis.
J Am Coll Cardiol
August 2025
Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; National Heart Centre Singapore, Singapore; Duke-NUS Medical School, Singapore; Saw Swee Hock School of Public Health, National University of Singapore & the National University Health
Background: In 2022, our network meta-analysis showed that a combination of β-blockers, angiotensin receptor-neprilysin inhibitors (ARNi), mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter 2 inhibitors (SGLT2i) was most effective in reducing all-cause mortality in heart failure with reduced ejection fraction (HFrEF). This study updates the treatment benefit by including additional large randomized controlled trials (RCTs) since 2022, including the Vericiguat Global Study in Participants with Chronic Heart Failure (VICTOR) trial.
Objectives: To evaluate and compare regimens of pharmacotherapy in patients with HFrEF.